Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage - PubMed (original) (raw)
. 1999 Jan 1;162(1):168-75.
Affiliations
- PMID: 9886383
Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
M S Labeur et al. J Immunol. 1999.
Abstract
Bone marrow-derived dendritic cells (BmDC) are potent APC and can promote antitumor immunity in mice when pulsed with tumor Ag. This study aimed to define the culture conditions and maturation stages of BmDC that enable them to optimally function as APC in vivo. BmDC cultured under various conditions (granulocyte-macrophage CSF (GM-CSF) or GM-CSF plus IL-4 alone or in combination with Flt3 ligand, TNF-alpha, LPS, or CD40 ligand (CD40L)) were analyzed morphologically, phenotypically, and functionally and were tested for their ability to promote prophylactic and/or therapeutic antitumor immunity. Each of the culture conditions generated typical BmDC. Whereas cells cultured in GM-CSF alone were functionally immature, cells incubated with CD40L or LPS were mature BmDC, as evident by morphology, capacity to internalize Ag, migration into regional lymph nodes, IL-12 secretion, and alloantigen or peptide Ag presentation in vitro. The remaining cultures exhibited intermediate dendritic cell maturation. The in vivo Ag-presenting capacity of BmDC was compared with respect to induction of both protective tumor immunity and immunotherapy of established tumors, using the poorly immunogenic squamous cell carcinoma, KLN205. In correspondence to their maturation stage, BmDC cultured in the presence of CD40L exhibited the most potent immunostimulatory effects. In general, although not entirely, the capacity of BmDC to induce an antitumor immune response in vivo correlated to their degree of maturation. The present data support the clinical use of mature, rather than immature, tumor Ag-pulsed dendritic cells as cancer vaccines and identifies CD40L as a potent stimulus to enhance their in vivo Ag-presenting capacity.
Similar articles
- Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.
Curiel-Lewandrowski C, Mahnke K, Labeur M, Roters B, Schmidt W, Granstein RD, Luger TA, Schwarz T, Grabbe S. Curiel-Lewandrowski C, et al. J Immunol. 1999 Jul 1;163(1):174-83. J Immunol. 1999. PMID: 10384114 - Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique.
Grauer O, Wohlleben G, Seubert S, Weishaupt A, Kämpgen E, Gold R. Grauer O, et al. Histochem Cell Biol. 2002 Apr;117(4):351-62. doi: 10.1007/s00418-002-0384-4. Epub 2002 Feb 16. Histochem Cell Biol. 2002. PMID: 11976908 - Cytokines in the generation and maturation of dendritic cells: recent advances.
Zou GM, Tam YK. Zou GM, et al. Eur Cytokine Netw. 2002 Apr-Jun;13(2):186-99. Eur Cytokine Netw. 2002. PMID: 12101074 Review. - The dendritic cell: its potent role in the respiratory immune response.
Lambrecht BN, Pauwels RA, Bullock GR. Lambrecht BN, et al. Cell Biol Int. 1996 Feb;20(2):111-20. doi: 10.1006/cbir.1996.0015. Cell Biol Int. 1996. PMID: 8935155 Review.
Cited by
- Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation.
Fujimoto H, Fukuzato S, Kanno K, Akutsu T, Ohdaira H, Suzuki Y, Urashima M. Fujimoto H, et al. Nutrients. 2023 Oct 13;15(20):4361. doi: 10.3390/nu15204361. Nutrients. 2023. PMID: 37892436 Free PMC article. Clinical Trial. - Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination.
Li X, Wichai N, Wang J, Liu X, Yan H, Wang Y, Luo M, Zhou S, Wang K, Li L, Miao L. Li X, et al. Acupunct Herb Med. 2022 Sep;2(3):196-206. doi: 10.1097/HM9.0000000000000046. Epub 2022 Dec 8. Acupunct Herb Med. 2022. PMID: 37808346 Free PMC article. Review. - TIRAP, TRAM, and Toll-Like Receptors: The Untold Story.
Lannoy V, Côté-Biron A, Asselin C, Rivard N. Lannoy V, et al. Mediators Inflamm. 2023 Mar 7;2023:2899271. doi: 10.1155/2023/2899271. eCollection 2023. Mediators Inflamm. 2023. PMID: 36926280 Free PMC article. Review. - Nanomedicine for Combination Urologic Cancer Immunotherapy.
Tian Y, Liu Z, Wang J, Li L, Wang F, Zhu Z, Wang X. Tian Y, et al. Pharmaceutics. 2023 Feb 6;15(2):546. doi: 10.3390/pharmaceutics15020546. Pharmaceutics. 2023. PMID: 36839868 Free PMC article. Review. - Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy.
Veiga RN, Zambalde ÉP, Cox L, Jucoski TS, Kohler AF, Carvalho TM, Rodrigues AC, Ludwig B, Crowley K, de Oliveira JC, Cortez MA. Veiga RN, et al. Adv Exp Med Biol. 2022;1385:75-108. doi: 10.1007/978-3-031-08356-3_3. Adv Exp Med Biol. 2022. PMID: 36352211
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous